The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIV

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMetroHealth Medical Center

About this trial

The purpose of The EXPAND study is to develop and pilot a pharmacist led model of medication delivery. Following a co-design phase, patients may receive injections at satellite pharmacies by a licensed pharmacist. The acceptability, appropriateness, and feasibility of this approach and standard in clinic administration by a nurse will be assessed.

Eligibility criteria

Qualifiers

18 years of age and older

diagnosed with HIV by approved HIV screen and confirmation test

currently on CAB+RPV LA every 4 or 8 weeks

has received at least two doses of CAB+PRV LA

Disqualifiers

individuals who are unable or unwilling to adhere to the study protocol

unable to speak/comprehend English

insurance coverage for medication through medical benefit

Trial design

Treatments tested in this trial

  • Model of care delivery for long-acting injectable ART

Treatment groups

164 Participants
are divided into 3 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

MetroHealth Medical Center

Lead sponsor

ViiV Healthcare

Collaborator